1330 related articles for article (PubMed ID: 26219858)
41. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
42. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
43. Nonalcoholic fatty liver disease in children: recent practice guidelines, where do they take us?
Aggarwal A; Puri K; Thangada S; Zein N; Alkhouri N
Curr Pediatr Rev; 2014; 10(2):151-61. PubMed ID: 25088269
[TBL] [Abstract][Full Text] [Related]
44. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
Anstee QM; Day CP
Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
[TBL] [Abstract][Full Text] [Related]
45. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
46. How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Libman H; Jiang ZG; Tapper EB; Reynolds EE
Ann Intern Med; 2019 Aug; 171(3):199-207. PubMed ID: 31382287
[TBL] [Abstract][Full Text] [Related]
47. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.
Zhang JZ; Cai JJ; Yu Y; She ZG; Li H
Gene Expr; 2019 Nov; 19(3):187-198. PubMed ID: 31010457
[TBL] [Abstract][Full Text] [Related]
48. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
Carr RM; Oranu A; Khungar V
Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
[TBL] [Abstract][Full Text] [Related]
49. Management of nonalcoholic fatty liver disease in the Middle East.
Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
[TBL] [Abstract][Full Text] [Related]
50. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
[TBL] [Abstract][Full Text] [Related]
51. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
52. The Future of Nonalcoholic Fatty Liver Disease Treatment.
Mazhar K
Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
[TBL] [Abstract][Full Text] [Related]
53. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.
Rich NE; Oji S; Mufti AR; Browning JD; Parikh ND; Odewole M; Mayo H; Singal AG
Clin Gastroenterol Hepatol; 2018 Feb; 16(2):198-210.e2. PubMed ID: 28970148
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
[TBL] [Abstract][Full Text] [Related]
55. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
56. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
[TBL] [Abstract][Full Text] [Related]
57. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
58. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
Lai J; Wang HL; Zhang X; Wang H; Liu X
Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
[TBL] [Abstract][Full Text] [Related]
59. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
60. Epidemiology and natural history of non-alcoholic fatty liver disease.
Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
